Finasteride lowers risk for diagnosis with prostate cancer WITHOUT increased risk for prostate cancer-specific mortality

Something that most of us seem to have managed to “miss” at the American Urological Association (AUA) annual meeting in San Francisco in May was an update from Dr. Ian Thompson on the 25-year outcomes of the Prostate Cancer Prevention Trial (PCPT). It has the potential to be rather important! … READ MORE …

But can exercise lower risk for prostate cancer diagnosis or progression?

In an incidentally timely manner, the May issue of Annals of Oncology carries a systematic review and meta-analysis of data on physical activity and risk for prostate cancer. … READ MORE …

Exercise alone: no evidence that this can lower prostate cancer risk

It should come as no great surprise to anyone that one’s level of physical activity is not necessarily linked, on its own, to one’s risk for diagnosis with prostate cancer. … READ MORE …

Anticoagulation therapy and prostate cancer prevention

Today’s “hot news story” in the cancer world is that a very widely used drug called warfarin (often still known as Coumadin) may be able to protect people from  the risks of getting diagnosed with at least some cancers. But … READ MORE …

Of statins and the prevention and treatment of prostate cancer

The question of whether or not to take a statin to either prevent or actually help in the treatment of prostate cancer has potentially just become moot for many men in America … thanks to new guidance from the US Preventive Services Task Force (USPSTF). … READ MORE …

Statins in the prevention and management of prostate cancer: an update

A recent review article in the journal Nature Reviews: Urology has concluded that, while we are learning a lot more about the potential role(s) of statins in the prevention and management of prostate cancer, we still have no definitive evidence of their value. … READ MORE …

Suggestions of bias in decisions about who got biopsies in the SELECT trial

A re-analysis of data from men participating in the placebo arms of the Prostate Cancer Prevention Trial (PCPT) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT) has suggested a problem with bias in decisions about who gets biopsies during certain types of clinical trial. … READ MORE …